Long‐term therapy of chronic delta hepatitis with peginterferon alfa

• Published in: Alimentary pharmacology & therapeutics Vol. 40; no. 1; pp. 93 - 104
• Main Authors: Heller, T., Rotman, Y., Koh, C., Clark, S., Haynes‐Williams, V., Chang, R., McBurney, R., Schmid, P., Albrecht, J., Kleiner, D. E., Ghany, M. G., Liang, T. J., Hoofnagle, J. H.
• Format: Journal Article
• Language: English
• Published: Oxford Blackwell 01.07.2014
• Subjects: Adolescent; Adult; Aged; Angiogenesis Inhibitors - therapeutic use; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Biological and medical sciences; Disease Progression; Dose-Response Relationship, Drug; Female; Hepatitis B Surface Antigens - blood; Hepatitis D virus; Hepatitis D, Chronic - complications; Hepatitis D, Chronic - drug therapy; Human viral diseases; Humans; Infectious diseases; Interferon-alpha - administration & dosage; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Liver Cirrhosis - etiology; Liver Cirrhosis - virology; Male; Medical sciences; Middle Aged; Polyethylene Glycols - administration & dosage; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Prospective Studies; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - therapeutic use; Time Factors; Treatment Outcome; Viral diseases; Viral hepatitis; Young Adult; Infection; Chronic; Treatment; Viral disease; Viral hepatitis delta; Cytokine; Digestive diseases; Hepatic disease; Interferon; Pegylated form; Long term

Summary Background Chronic delta hepatitis virus (HDV) infection rapidly progresses to cirrhosis. Treatment with peginterferon for up to 2 years is often without durable response. Aim To examine the efficacy and safety of long‐term peginterferon in achieving a durable response. Methods Treatment was...